BMI View: Like several other African countries, low per capita healthcare and pharmaceutical expenditure mean that Cameroon will not be able to attract significant investments from multinational pharmaceutical companies. Weak business environment and poor governance are two key shortcomings, and as a result we maintain that Cameroon must see economic improvements before any success can trickle down to the healthcare sector. Headline Expenditure Projections ? Pharmaceuticals: XAF131.4bn (US$260mn) in 2012 to XAF148.1bn (US$300mn) in 2013; +12.7% in local currency terms and +14.8% in US dollar terms. Forecast broadly in line with Q313. ? Healthcare: XAF701.3bn (US$1.41bn) in 2012 to XAF750.6bn …
Order / Buy a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=113301.
Complete report details with Table of Contents and more @ http://www.rnrmarketresearch.com/cameroon-pharmaceuticals-and-healthcare-report-q4-2013-market-report.html.
No comments:
Post a Comment